Short Interest in Allarity Therapeutics, Inc. (NASDAQ:ALLR) Rises By 392.7%

Allarity Therapeutics, Inc. (NASDAQ:ALLR) was the recipient of a significant increase in short interest in September. As of September 15th, there was short interest totalling 94,600 shares, an increase of 392.7% from the August 31st total of 19,200 shares. Currently, 8.9% of the company’s stock are short sold. Based on an average daily volume of 448,700 shares, the short-interest ratio is presently 0.2 days.

Allarity Therapeutics Stock Performance

Shares of ALLR stock traded up $0.05 on Wednesday, reaching $2.27. 320,115 shares of the stock were exchanged, compared to its average volume of 210,195. Allarity Therapeutics has a twelve month low of $1.78 and a twelve month high of $666.00. The business’s 50 day moving average price is $0.69 and its 200 day moving average price is $1.57.

Allarity Therapeutics (NASDAQ:ALLR) last announced its quarterly earnings results on Monday, August 5th. The company reported ($0.11) earnings per share for the quarter. Sell-side analysts predict that Allarity Therapeutics will post -78.08 earnings per share for the current fiscal year.

Allarity Therapeutics Company Profile

Allarity Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme.